Recombinant Botulinum Toxin Composition for Long-Term Activity Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing botulinum toxin proteins are inefficient, costly, and pose biological risks due to the use of pathogenic Clostridium botulinum, and the formulations have poor durability and activity maintenance.
Innovation Solution
A recombinant botulinum toxin protein composition comprising botulinum toxin protein, human serum albumin, saccharides, and salts, with specific mass percentages, is prepared by mixing and lyophilizing, using non-pathogenic Escherichia coli expression to reduce biological risks and improve stability and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If botulinum toxin is produced by Clostridium botulinum, then the toxin has the required biological activity, but the production process poses biological risks and has low efficiency
Solution Approach 1:
The patent uses recombinant DNA technology to copy the botulinum toxin gene into Escherichia coli, creating a safe replica that produces the toxin protein without requiring the pathogenic Clostridium botulinum bacterium. This eliminates biological safety risks while maintaining production capability
Solution Approach 2:
The patent introduces Escherichia coli as an intermediary host organism to produce the botulinum toxin protein. E. coli serves as a safe mediator that can be genetically engineered to express the toxin gene, replacing the dangerous Clostridium botulinum while maintaining industrial production efficiency
2Manufacturing precision
If botulinum toxin is extracted from multi-protein complex, then the toxin can be obtained, but the process is complex and time-consuming with low purity
Solution Approach 1:
The patent directly extracts only the necessary botulinum toxin gene from the source and inserts it into E. coli, taking out the essential functional element while leaving behind the complex multi-protein environment of Clostridium botulinum. This results in simplified production with high purity toxin protein
Solution Approach 2:
The patent creates a localized expression system where only the botulinum toxin protein is produced in E. coli, rather than extracting from a complex mixture. This localized production approach ensures high purity and simplifies the manufacturing process
3Duration of action of stationary object
If conventional formulation is used, then the toxin can be administered, but the activity durability is poor
Solution Approach 1:
The patent creates a composite formulation containing botulinum toxin protein combined with human serum albumin and saccharides. This composite material structure protects the toxin protein and maintains its biological activity over extended periods, solving the durability problem
Solution Approach 2:
The patent optimizes formulation parameters including pH, ionic strength, and composition ratios of excipients to create stable conditions that maintain toxin protein activity. By adjusting these physical-chemical parameters, the formulation achieves improved activity durability and reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant botulinum toxin protein composition maintains high activity, reduces toxicity, and facilitates safe, efficient industrial production, expanding its application range with improved purity and stability.
Implementation Method 1
human serum albumin has a mass percentage in the range of 0.2% to 2%
Implementation Method 2
a saccharide, and a salt
Implementation Method 3
The preparation method for a botulinum toxin protein composition, comprising mixing the components and lyophilizing to obtain the composition
Data Source
AI summary
The present invention provides a botulinum toxin protein composition, mainly comprising botulinum toxin protein, a saccharide, a salt, and human serum albumin. The botulinum toxin protein composition of the present invention features good activity and stable properties, and can maintain the activity of the botulinum toxin protein at a high level after long-term storage.